• Explore /
  • Poster
  • / Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience.

Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience.

Abstract Poster

Authors

null

Renee Maria Saliby

Dana-Farber Cancer Institute, Boston, MA

Renee Maria Saliby , Tejas Jammihal , Chris Labaki , Wanling Xie , Robert J. Motzer , Thomas Powles , Brian I. Rini , Laurence Albiges , Sumanta K. Pal , Rana R. McKay , Sabina Signoretti , Sachet A. Shukla , Eliezer Mendel Van Allen , David A. Braun , Toni K. Choueiri

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4531)

DOI

10.1200/JCO.2022.40.16_suppl.4531

Abstract #

4531

Poster Bd #

22

Abstract Disclosures

Similar Posters

First Author: Viktor Grünwald

First Author: Aarti K. Bhatia

First Author: Ulka N. Vaishampayan

Poster

2022 ASCO Genitourinary Cancers Symposium

Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).

Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).

First Author: Matthew Scott Ernst